Guilford Gliadel

Sales force of approximately 25 to 35 reps from Cardinal Health's sales and marketing services subsidiary, formerly MarketForce, will market carmustine wafer following reacquisition of rights from Aventis. Aventis will continue to market the malignant brain cancer treatment until year-end during the transition period